Hepatic Resection After Neoadjuvant Chemotherapy for Colorectal Liver Metastases

Kaibori, Masaki; Iwamoto, Yoshinori; Ishizaki, Morihiko; Matsui, Kosuke; Okazaki, Satoshi; Kanbara, Tatsuya; Inoue, Kentaro; Tokuhara, Katsuji; Yoshioka, Kazuhiko; Kwon, A‐Hon

doi:10.4030/jjcs.37.696

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported 3-year and 5-year survival rates were 40%-80% and 30%-76%, respectively; these figures are promising when compared with the 5-year survival rate of 18.8% in patients with stage IV colorectal cancer. 25,28,29,[188][189][190][191][192][193][194][195][196][197][198][199] Based on the large treatment effect, conversion surgery after systemic neoadjuvant chemotherapy in patients with liver metastases from colorectal cancer that were judged initially as unresectable can be weakly recommended, but with only low quality of evidence.…”

Section: Recommendationmentioning

confidence: 99%

Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021

Yamamoto

Yoshida

Furuse

et al. 2020

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Background Hepatectomy is standard treatment for colorectal liver metastases; however, it is unclear whether liver metastases from other primary cancers should be resected or not. The Japanese Society of Hepato‐Biliary‐Pancreatic Surgery therefore created clinical practice guidelines for the management of metastatic liver tumors. Methods Eight primary diseases were selected based on the number of hepatectomies performed for each malignancy per year. Clinical questions were structured in the population, intervention, comparison, and outcomes (PICO) format. Systematic reviews were performed, and the strength of recommendations and the level of quality of evidence for each clinical question were discussed and determined. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations. Results The eight primary sites were grouped into five categories based on suggested indications for hepatectomy and consensus of the guidelines committee. Fourteen clinical questions were devised, covering five topics: (1) diagnosis, (2) operative treatment, (3) ablation therapy, (4) the eight primary diseases, and (5) systemic therapies. The grade of recommendation was strong for one clinical question and weak for the other 13 clinical questions. The quality of the evidence was moderate for two questions, low for 10, and very low for two. A flowchart was made to summarize the outcomes of the guidelines for the indications of hepatectomy and systemic therapy. Conclusions These guidelines were developed to provide useful information based on evidence in the published literature for the clinical management of liver metastases, and they could be helpful for conducting future clinical trials to provide higher‐quality evidence.

show abstract